

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

**Patients scheduled for surgery should have the following antibiotics administered prior to their procedure:**

- Vancomycin and ciprofloxacin are to be initiated 60 to 120 minutes prior to incision, and all other antibiotics are to be initiated within 60 minutes of incision
- Carefully evaluate allergy histories before using alternative agents - the majority of patients with listed penicillin allergies can safely be given cephalosporins or carbapenems
- If the patient has multiple known antibiotic drug allergies, is colonized with or has a history of a recent multi-drug infection, administer antibiotics as indicated or consider an outpatient Infectious Diseases consultation
- Discontinue all antibiotics within 24 hours of first dose except for: 1) Treatment of established infection, 2) Prophylaxis of prosthesis in the setting of postoperative co-located percutaneous drains, 3) Intraoperative findings that raise the wound classification above 2 (e.g., spillage of enteric contents, purulent fluid, etc.) All of these require appropriate documentation.
- See [Appendix A](#) for intraoperative redosing recommendations

Disease Site	No Penicillin Allergy	Patients with Penicillin Allergy
Breast / Melanoma / Plastics	<ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: cefazolin 3 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• <u>Less than 70 kg</u>: clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: clindamycin 900 mg IV</li> </ul>
Head / Neck (ENT – Clean)	<ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: cefazolin 3 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• <u>Less than 70 kg</u>: clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: clindamycin 900 mg IV</li> </ul>
Head / Neck (ENT – Clean Contaminated)	<ul style="list-style-type: none"> <li>• Ampicillin and sulbactam 3 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• Levofloxacin 500 mg IV <b>and</b></li> <li>• <u>Less than 70 kg</u>: clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: clindamycin 900 mg IV</li> </ul>
Neurosurgery	Skull base ONLY: <ul style="list-style-type: none"> <li>• Ampicillin and sulbactam 3 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• <u>Less than or equal to 70 kg</u>: vancomycin 1 gram IV</li> <li>• <u>Between 70 kg and 100 kg</u>: vancomycin 1.5 grams IV</li> <li>• <u>Greater than or equal to 100 kg</u>: vancomycin 2 grams IV</li> </ul>
	All other types: <ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: cefazolin 3 grams IV</li> </ul>	<b>or</b> <ul style="list-style-type: none"> <li>• <u>Less than 70 kg</u>: clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: clindamycin 900 mg IV</li> </ul>
Vascular	<ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: cefazolin 3 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• <u>Less than or equal to 70 kg</u>: vancomycin 1 gram IV</li> <li>• <u>Between 70 kg and 100 kg</u>: vancomycin 1.5 grams IV</li> <li>• <u>Greater than or equal to 100 kg</u>: vancomycin 2 grams IV</li> </ul> <b>or</b> <ul style="list-style-type: none"> <li>• <u>Less than 70 kg</u>: clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: clindamycin 900 mg IV</li> </ul>
Orthopedics	Pelvic surgery ONLY: <ul style="list-style-type: none"> <li>• <u>Ceftriaxone</u> 2 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• <u>Less than or equal to 70 kg</u>: vancomycin 1 gram IV</li> <li>• <u>Between 70 kg and 100 kg</u>: vancomycin 1.5 grams IV</li> <li>• <u>Greater than or equal to 100 kg</u>: vancomycin 2 grams IV</li> </ul>
	All other types: <ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: cefazolin 3 grams IV</li> </ul>	<b>or</b> <ul style="list-style-type: none"> <li>• <u>Less than 70 kg</u>: clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: clindamycin 900 mg IV</li> </ul>

Vancomycin prophylaxis should be considered for patients with known MRSA colonization or at high risk for MRSA colonization in the absence of surveillance data (e.g., patients with recent hospitalization, nursing-home residents, hemodialysis patients). *ASHP guidelines*

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

**Patients scheduled for surgery should have the following antibiotics administered prior to their procedure:**

- Vancomycin and ciprofloxacin are to be initiated 60 to 120 minutes prior to incision, and all other antibiotics are to be initiated within 60 minutes of incision
- Carefully evaluate allergy histories before using alternative agents - the majority of patients with listed penicillin allergies can safely be given cephalosporins or carbapenems
- If the patient has multiple known antibiotic drug allergies, is colonized with or has a history of a recent multi-drug infection, administer antibiotics as indicated or consider an outpatient Infectious Diseases consultation
- Discontinue all antibiotics within 24 hours of first dose except for: 1) Treatment of established infection, 2) Prophylaxis of prosthesis in the setting of postoperative co-located percutaneous drains, 3) Intraoperative findings that raise the wound classification above 2 (e.g., spillage of enteric contents, purulent fluid, etc.) All of these require appropriate documentation.
- See [Appendix A](#) for intraoperative redosing recommendations

Disease Site	No Penicillin Allergy	Patients with Penicillin Allergy
GI (Clean)	<ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: cefazolin 3 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• <u>Less than 70 kg</u>: clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: clindamycin 900 mg IV</li> </ul>
GI	Gastric, Pancreas, or Liver: <ul style="list-style-type: none"> <li>• Cefoxitin 2 grams IV <b>or</b></li> <li>• Ertapenem 1 gram IV</li> </ul> Colorectal: <ul style="list-style-type: none"> <li>• Ertapenem 1 gram IV <b>and</b> preoperative bowel preparation<sup>1</sup></li> </ul>	Gastric, Pancreas, or Liver: <ul style="list-style-type: none"> <li>• Ciprofloxacin 400 mg IV <b>and</b> metronidazole 500 mg IV</li> </ul> Colorectal: <ul style="list-style-type: none"> <li>• Ciprofloxacin 400 mg IV <b>and</b> metronidazole 500 mg IV <b>and</b> pre-operative bowel preparation<sup>1</sup></li> </ul>
Gynecologic	GI procedures unlikely <sup>2</sup> : <ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: cefazolin 2 grams IV <b>or</b></li> <li>• <u>Greater than or equal to 120 kg</u>: cefazolin 3 grams IV</li> </ul> GI procedures likely: <ul style="list-style-type: none"> <li>• Ertapenem 1 gram IV <b>and</b> preoperative bowel preparation<sup>1</sup></li> </ul>	GI procedure unlikely: <ul style="list-style-type: none"> <li>• Ciprofloxacin 400 mg IV <b>and</b> metronidazole 500 mg IV</li> </ul> GI procedure likely: <ul style="list-style-type: none"> <li>• Ciprofloxacin 400 mg IV <b>and</b> metronidazole 500 mg IV <b>and</b> pre-operative bowel preparation<sup>1</sup></li> </ul>
Thoracic / Pulmonary / Esophageal	Ampicillin and sulbactam 3 grams IV	<ul style="list-style-type: none"> <li>• <u>Less than or equal to 70 kg</u>: vancomycin 1 gram IV</li> <li>• <u>Between 70 kg and 100 kg</u>: vancomycin 1.5 grams IV</li> <li>• <u>Greater than or equal to 100 kg</u>: vancomycin 2 grams IV <b>and</b></li> <li>• Ciprofloxacin 400 mg IV</li> </ul>

<sup>1</sup> Patients undergoing colorectal resection should be considered for preoperative mechanical and oral antibiotic bowel preparation

<sup>2</sup> Patients with unanticipated GI procedures should receive ertapenem 1 gram IV intraoperatively as soon as need is identified

MRSA screening should be performed on patients hospitalized within 30 days of procedure, transferred from skilled nursing facilities, with percutaneous lines/catheters, or with HIV. Any surgical patient with a history of MRSA infection or positive MRSA screening should receive vancomycin 1 gram IV as part of surgical prophylaxis. If vancomycin is being ordered based on standard disease site recommendations, a second dose is not necessary. Vancomycin prophylaxis should be considered for patients with known MRSA colonization or at high risk for MRSA colonization in the absence of surveillance data (e.g., patients with recent hospitalization, nursing-home residents, hemodialysis patients). *ASHP guidelines.*

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

**Patients scheduled for surgery should have the following antibiotics administered prior to their procedure:**

- Vancomycin and ciprofloxacin are to be initiated 60 to 120 minutes prior to incision, and all other antibiotics are to be initiated within 60 minutes of incision
- Carefully evaluate allergy histories before using alternative agents - the majority of patients with listed penicillin allergies can safely be given cephalosporins or carbapenems
- If the patient has multiple known antibiotic drug allergies, is colonized with or has a history of a recent multi-drug infection, administer antibiotics as indicated or consider an outpatient Infectious Diseases consultation
- Discontinue all antibiotics within 24 hours of first dose except for: 1) Treatment of established infection, 2) Prophylaxis of prosthesis in the setting of postoperative co-located percutaneous drains, 3) Intraoperative findings that raise the wound classification above 2 (e.g., spillage of enteric contents, purulent fluid, etc.) All of these require appropriate documentation.
- See [Appendix A](#) for intraoperative redosing recommendations

Disease Site	No Penicillin Allergy	Patients with Penicillin Allergy
Genitourinary	For Endoscopy/Transurethral Resection of Bladder Tumor (TURBT): Ciprofloxacin 500 mg PO twice a day (or equivalent based on renal function/allergies) to start 1 day prior to procedure (prescription given in clinic).  Endoscopy or procedures: <ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: Cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: Cefazolin 3 grams IV</li> </ul> <u>or</u> <ul style="list-style-type: none"> <li>• Cefoxitin 2 grams IV <u>or</u></li> <li>• Ciprofloxacin 400 mg IV <u>and</u> metronidazole 500 mg IV Or</li> <li>• Gentamicin 1.5 mg/kg IV <u>and</u> metronidazole 500 mg IV</li> </ul>	Extended coverage (Option 1) <ul style="list-style-type: none"> <li>• <u>Less than 70 kg</u>: Clindamycin 600 mg IV</li> <li>• <u>Greater than or equal to 70 kg</u>: Clindamycin 900 mg IV</li> </ul> <u>and</u> <ul style="list-style-type: none"> <li>• Gentamicin 1.5 mg/kg IV <u>or</u> ciprofloxacin 400 mg IV</li> </ul> Limited coverage (Option 2) <ul style="list-style-type: none"> <li>• Ciprofloxacin 400 mg IV <u>or</u> 500 mg PO</li> </ul>
	Implanted prosthesis: <ul style="list-style-type: none"> <li>• <u>Less than 120 kg</u>: Cefazolin 2 grams IV</li> <li>• <u>Greater than or equal to 120 kg</u>: Cefazolin 3 grams IV</li> </ul>	<ul style="list-style-type: none"> <li>• <u>Less than or equal to 70 kg</u>: Vancomycin 1 gram IV</li> <li>• <u>Between 70 kg and 100 kg</u>: Vancomycin 1.5 grams IV</li> <li>• <u>Greater than or equal to 100 kg</u>: Vancomycin 2 grams IV</li> </ul> <u>and</u> <ul style="list-style-type: none"> <li>• Gentamicin 1.5 mg/kg IV</li> </ul>

MRSA screening should be performed on patients hospitalized within 30 days of procedure, transferred from skilled nursing facilities, with percutaneous lines/catheters, or with HIV. Any surgical patient with a history of MRSA infection or positive MRSA screening should receive Vancomycin 1 gram IV as part of surgical prophylaxis. If Vancomycin is being ordered based on standard disease site recommendations, a second dose is not necessary. Vancomycin prophylaxis should be considered for patients with known MRSA colonization or at high risk for MRSA colonization in the absence of surveillance data (e.g., patients with recent hospitalization, nursing-home residents, hemodialysis patients). *ASHP guidelines.*

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## APPENDIX A: Recommended IntraOp Redosing Intervals for Commonly Used Surgical Prophylaxis Antimicrobials for Adults with Normal Renal Function<sup>1</sup>

Antimicrobial	Half-life (hour)	Recommended Redosing Interval <sup>2</sup> From Initiation of Preoperative Dose (hour)
Ampicillin-sulbactam	0.8 - 1.3	4
Cefazolin	1.2 - 2.2	4
Cefoxitin	0.7 - 1.1	4
Ciprofloxacin <sup>3</sup>	3 - 7	N/A
Clindamycin	2 - 4	6
Ertapenem	3 - 5	N/A
Gentamicin <sup>4</sup>	2 - 3	N/A
Levofloxacin <sup>3</sup>	6 - 8	N/A
Metronidazole	6 - 8	N/A
Vancomycin <sup>5</sup>	4 - 8	N/A

<sup>1</sup> Patients with impaired renal function need individualized initial and secondary antibiotic dosing based on GFR and case type

<sup>2</sup> For antimicrobials with a short half-life (e.g., cefazolin, cefoxitin) used before long procedures, re-dosing in the operating room is recommended at an interval of approximately two times the half-life of the agent in patients with normal renal function. Recommended re-dosing intervals marked as “not applicable” (NA) are based on typical case length; for unusually long procedures, re-dosing may be needed.

<sup>3</sup> While fluoroquinolones have been associated with an increased risk of tendinitis/tendon rupture in all ages, use of these agents for single-dose prophylaxis is generally safe

<sup>4</sup> In general, gentamicin for surgical antibiotic prophylaxis should be limited to a single dose given preoperatively. Dosing is based on the patient's actual body weight. If the patient's actual weight is more than 20% above ideal body weight (IBW), the dosing weight (DW) can be determined as follows: DW = IBW with 0.4 (actual weight – IBW).

<sup>5</sup> Vancomycin prophylaxis should be considered for patients with known MRSA colonization or at high risk for MRSA colonization in the absence of surveillance data (e.g., patients with recent hospitalization, nursing home residents, hemodialysis patients). ASHP guidelines.

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

---

## SUGGESTED READINGS

- ACOG Committee on Practice Bulletins. (2006). ACOG practice bulletin no. 74: Antibiotic prophylaxis for gynecologic procedures. *Obstetrics and Gynecology*, 108(1), 225-234.
- American Society of Health-System Pharmacists. (2013). ASHP therapeutic guidelines on clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm*. 70:600-686.
- Antimicrobial prophylaxis for surgery. Treatment guidelines from the Medical Letter, 7(82), 47-52.
- Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., . . . American Society of Health-System Pharmacists. (2013). Clinical practice guidelines for antimicrobial prophylaxis in surgery. *American Journal of Health-System Pharmacy*, 70(3), 195-283.
- Bratzler, D. W., Houck, P. M., Surg Infect Prevention Guidelines, American College of Surgeons, American College of Osteopathic Surgeons, Association of periOperative Registered Nurses, . . . for the Surgical Infection Prevention Guidelines Writers Workgroup. (2004). Antimicrobial prophylaxis for surgery: An advisory statement from the national surgical infection prevention project. *Clinical Infectious Diseases*, 38(12), 1706-1715.
- Dellinger, E. P., Gross, P. A., Barrett, T. L., Krause, P. J., Martone, W. J., John E. McGowan, J., . . . Wenzel, R. P. (1994). Quality standard for antimicrobial prophylaxis in surgical procedures. *Clinical Infectious Diseases*, 18(3), 422-427.
- Edwards, B. L., Stukenborg, G. J., Brenin, D. R., & Schroen, A. T. (2014). Use of prophylactic postoperative antibiotics during surgical drain presence following mastectomy. *Annals of Surgical Oncology*, 21(10), 3249-3255.
- Gilbert, D. N., & Moellering, R. C. Jr. (2011). The Sanford Guide to Antimicrobial Therapy. 41<sup>st</sup> ed. Hyde Park, VT: *Antimicrobial Therapy Inc*. pp.177-180.
- Itani, K. M. F., Wilson, S. E., Awad, S. S., Jensen, E. H., Finn, T. S., & Abramson, M. A. (2006). Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. *The New England Journal of Medicine*, 355(25), 2640-2651.
- Mangram A. J., Horan, T. C., Pearson, M. L., (1999). Guidelines for prevention of surgical site infection. *Infect Control Hosp Epidemiol*. 20:247-280.
- Page, C. P., Bohnen, J. M. A., Fletcher, J. R., McManus, A. T., Solomkin, J. S., & Wittmann, D. H. (1993). Antimicrobial prophylaxis for surgical wounds: Guidelines for clinical care. *Archives of Surgery*, 128(1), 79-88.
- Phillips, B. T., Bishawi, M., Dagum, A. B., Khan, S. U., & Bui, D. T. (2013). A systematic review of antibiotic use and infection in breast reconstruction: What is the evidence? *Plastic and Reconstructive Surgery*, 131(1), 1-13.

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

---

## DEVELOPMENT CREDITS

This practice consensus statement is based on majority opinion of the Adult Surgical Antibiotic Prophylaxis workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Thomas Aloia, MD (Surgical Oncology)  
Samuel L. Aitken, Pharm.D (Pharmacy Clinical Programs)<sup>†</sup>  
Justin Earl Bird, MD (Orthopaedic Oncology)  
Collin Dinney, MD (Urology)  
David Gershenson, MD (Gynecologic Oncology & Reproductive Medicine)  
Linda Graviss, MT (Infection Control)  
Valerae Lewis, MD (Orthopaedic Oncology)  
Victor Mulanovich, MD (Infectious Diseases)<sup>†</sup>  
Sally Raty, MD (Anesthesiology & PeriOperative Medicine)

Geoffrey Robb, MD (Plastic Surgery)  
Raymond Sawaya, MD (Neurosurgery)  
Stephen Swisher, MD (Thoracic & Cardiovascular Surgery)  
George Michael Viola, MD (Infectious Diseases)  
Jeffrey Weinberg, MD (Neurosurgery)  
Randal Weber, MD (Head & Neck Surgery)  
Anita Williams, BS<sup>♦</sup>  
Sonal Yang, PharmD, BCPS<sup>♦</sup>

<sup>†</sup>Core Development Team

<sup>♦</sup>Clinical Effectiveness Development Team